ITN’s ACCESS Trial for Lupus Nephritis Enrolls First Patient
The Feinstein Institute in New York City has enrolled the first patient in the Immune Tolerance Network’s ACCESS clinical trial of abatacept and cyclophosphamide for lupus nephritis. The study is seeking to enroll 100 participants at clinical centers across the US and Mexico over the next three years.